» Articles » PMID: 38170436

TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort

Overview
Journal Adv Ther
Date 2024 Jan 3
PMID 38170436
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In Colombia, thyroid cancer ranks among the highest incidences, yet our population lacks studies on its molecular profile. This study aims to characterize clinical, histopathologic and molecular data in a Colombian cohort with papillary thyroid carcinoma (PTC).

Methods: A retrospective review of clinical history, clinicopathologic characteristics, treatment and 5-10-year follow-up for all patients was done. DNA and RNA were extracted from formalin-fixed paraffin-embedded (FFPE) tissue using the Quick-DNA & RNA FFPE Min iPrep kit (Zymo Research). Next-generation sequencing (NGS) analysis was performed with SOPHiA Solid Tumor Solutions kit (SOPHiA GENETICS). Tumor mutation genomic analysis used SOPHiA DDM™ platform, with descriptive analysis reporting frequencies, means and associations via chi-square analysis.

Results: Among 231 sequenced patients, mean age at diagnosis was 46 (± 12.35) years, with higher frequency in women (81.82%). Two cases were reclassified as non-invasive follicular thyroid neoplasm (NIFT-P); an NRAS mutation was found in one of them. Predominant histologic subtype was classic PTC (57.64%) followed by tall cell (28.82%). Of the 229 sequenced carcinomas, mutations were identified in 186 cases, including BRAF, IDH1, RAS and PIK3CA. Notable copy number variations (CNVs) were PDGFRA, CDK4 and KIT, with RET being the most frequent gene fusion, including CCDC6-RET in two classic subtype cases.

Conclusion: This is the first study in Colombia (TIROSEC) to our knowledge that integrates molecular and histopathologic profiles enriching our local comprehension and knowledge of PTC. The identification of target mutations such as BRAF, RET and NTRK fusions holds the potential to guide targeted therapies for tumor recurrence and predict aggressive behavior.

References
1.
Fitzmaurice C, Akinyemiju T, Al Lami F, Alam T, Alizadeh-Navaei R, Allen C . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018; 4(11):1553-1568. PMC: 6248091. DOI: 10.1001/jamaoncol.2018.2706. View

2.
Kitahara C, Sosa J . Understanding the ever-changing incidence of thyroid cancer. Nat Rev Endocrinol. 2020; 16(11):617-618. PMC: 7476643. DOI: 10.1038/s41574-020-00414-9. View

3.
Bates M, Lamas M, Randle R, Long K, Pitt S, Schneider D . Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?. Surgery. 2017; 163(1):118-123. PMC: 5736421. DOI: 10.1016/j.surg.2017.05.028. View

4.
Baloch Z, LiVolsi V . Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow. Expert Rev Mol Diagn. 2005; 5(4):573-84. DOI: 10.1586/14737159.5.4.573. View

5.
LiVolsi V . Papillary thyroid carcinoma: an update. Mod Pathol. 2011; 24 Suppl 2:S1-9. DOI: 10.1038/modpathol.2010.129. View